Chemotherapy is the preferred treatment for malignancies. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Many mechanisms such as gene mutation, DNA methylation and histone modification have important roles in the resistance of cancer cells to chemotherapeutic agents. Climent suggested miR-125b was involved in the development of drug resistance by microRNA (miRNA) dysregulation. miRNAs are endogenously expressed small non-coding RNAs, which are evolutionarily conserved and function as regulators of gene expression. Much effort has been exerted in analyzing the role of miRNAs in the development of drug resistance in a variety of malignancies. Several research groups have shown that the expressions of miRNAs in chemoresistant cancer cells and their parental chemosensitive ones are different. The molecular targets and mechanisms of chemosensitivity and chemoresistance are also elucidated. This article reviews the functions of miRNAs in the development of drug resistance.
Introduction
MicroRNAs (miRNAs) are a new class of small, nonprotein-encoding RNAs that range in size from 19 to 25 nucleotides (nt) and have important roles in a variety of biologic processes. 1, 2 Like conventional protein-coding mRNA, miRNAs are transcribed by RNA polymerase II, spliced, capped and poly-adenylated (called primitive miRNA or pri-miRNA). Then primitive miRNA transcripts are processed by a RNase III endonuclease, Drosha, to the hairpin 'precursor' miRNAs that are B70 nt in animals or B100 nt in plants in the nucleus. 3 This hairpin precursor miRNA bounds to exportin-5 and RNA GTPase, which allows the transport of the molecules into the cytoplasm. The precursor miRNA is then processed into B22 nt miRNA duplexes by Dicer, which recognizes it through interaction with the 2 nt overhang at the 3 0 end. 4 The mature miRNA (the functional strand of the miRNA duplex) is incorporated into the RNA-induced silencing complex and then target the 3 0 untranslated region (3 0 UTR) of a specific mRNA by a 'seed' sequence (2B7 nt long) that is located near the 5 0 region of the miRNA. 5 The perfect or imperfect base pairing of miRNAs to the sequences of target mRNAs often induces mRNA degradation or translational repression. 6 Moreover, recent evidence suggests that miRNAs can also bind to the 5 0 UTR of target mRNAs and under specific conditions can induce translation upregulation of target mRNAs. 7, 8 miRNAs are involved in various biologic processes, including cell proliferation, cell differentiation, cell death, stress resistance and fat metabolism. miRNAs also act as either tumor suppressors or oncogenes to regulate tumor development and may contribute to tumor invasion. 1, 9, 10 Chemotherapy remains the primary treatment for both resectable and advanced cancers to improve overall survival and quality of life for patients. As the drug resistance was first documented experimentally in mouse leukemic cells that acquired resistance to methotrexate in a laboratory model in 1950, 11 overwhelming evidence has shown drug resistance is the main cause of treatment failure. Genomic and proteomic studies have yielded a wealth of novel insights into molecular targets and mechanisms of cancer chemosensitivity and chemoresistance. A recent study by Climent et al. 12 suggested that the increased sensitivity of breast cancer patients to anthracycline-based chemotherapy may be related to the deletion of chromosome 11q, a region containing miR-125b gene. This finding indicated a possible link between miRNAs dysregulation and cancer drug resistance.
Effect of miRNAs on chemotherapy was systematically studied by Blower et al. 13 as part of the Molecular Targets Program aimed at elucidating molecular targets and understanding mechanisms of chemosensitivity and chemoresistance. Comparison of the expression patterns of miRNAs and the potency patterns of the 3089 chemical compounds have shown significant correlations, suggesting that miRNAs have a role in chemoresistance (Table 1) .
This article reviews miRNAs and drug resistance. 
Breast cancer
Breast cancer is the most common malignant tumor in women, accounting for 31% of all female cancers. Over two-thirds of breast cancers show high concentrations of estrogen receptor (ER). Blocking the hormonal pathway with tamoxifen has been shown to be effective in these patients. In spite of the accomplishment of tamoxifen, a significant proportion of patients will experience disease progression because of either an intrinsic or acquired resistance to the drug. Miller et al.
14 using miRNA microarray analysis showed that eight miRNAs (miR-221, miR-222, miR-181, miR-375, miR-171, miR-213, miR-203 and miR-32) were upregulated and seven miRNAs (miR-21, miR-342, miR-489, miR-24, miR-27, miR-23 and miR-200) were downregulated in 4-hydroxytamoxifen-resistant (OHT(R)) cells, comparing with parental tamoxifen-sensitive MCF-7 cells. Upregulation of miR-221, miR-222, miR-181 and downregulation of miR-21, miR-342, miR-489 were validated by real-time reverse transcriptase-PCR. Expression of miR-221 and miR-222 was also significantly increased in HER2/neu-positive primary human breast cancer that is known to be resistant to endocrine therapy. The ectopic expression of miR-221/222 has rendered the parental MCF-7 cells resistant to tamoxifen. miR-221/222 functions as an oncogene by targeting cell cycle inhibitor p27kip1. 15 The protein and mRNA level of p27kip1 was reduced in OHT(R) cells and in miR-221/222-overexpressing MCF-7 cells, indicating that the effect of miR-221/222 in tamoxifen resistance is mediated by the loss of p27kip1 in breast cancer.
Fulvestrant, known as a selective ER downregulator, is the second-line drug given to breast cancer patients with ER-positive, tamoxifen-resistant tumors. However, most breast cancers eventually develop resistance to fulvestrant. Fourteen downregulated miRNAs (for example, let-7i, miR-346 and miR-638) and two upregulated miRNAs (miR-221 and miR-222) have been found in fulvestrant-resistant MCF-7-FR cells comparing with their drug-sensitive parental ER-positive MCF-7 cells. 16 Further studies have indicated that the 14 miRNAs are associated with the acquisition of fulvestrant resistance, for they are involved in the regulation of transforming growth factor-b pathway. 16 The loss of growth-inhibitory response to transforming growth factor-b is associated with breast neoplasia. 17, 18 ErbB2 signaling pathway is involved in establishing estrogen-independent growth in fulvestrant-resistant breast cancer cells. 19 Upregulated miR-221/222 targets the ErbB signaling pathway. 16 Although the majority of primary breast cancers are ERa-positive and respond to anti-estrogen therapy, up to one-third of patients lack ERa at the time of diagnosis. A fraction of breast cancers that are initially ERa-positive will lose ERa expression as the diseases progress. 20 These patients fail to respond to anti-estrogen therapy and have a poor prognosis. The lack of expression of ERa is a mechanism of tamoxifen resistance in breast cancer.
miR-221 and miR-222 were elevated in the ERanegative cell lines and primary tumors comparing with ERa-positive breast cancers. 21 Transfection of miR-221 and miR-222 to MCF-7 and T47D cell lines resulted in the decreased production of the protein but not mRNA levels of ERa and induced the two cell lines to become resistance to tamoxifen, whereas knockdown of miR-221 and miR-222 in MDA-MB-468 cells partially restored ERa in ERa protein-negative/mRNA-positive cells and reduced resistance to tamoxifen. Through direct interaction with the 3 0 UTR of ERa, miR-221 and miR-222 inhibit ERa translation and provide a molecular mechanism of ERa regulation at the post-transcriptional level in breast cancer. Although miR-221 and miR-222 have an identical eight-nucleotide seed sequence to regulate ERa, the effect of the combined knockdown of both of them on tamoxifen-induced cell death is more significant than that of either one alone. 21 In the future, miR-221 and miR-222 may serve as potential therapeutic targets for a subset of ERa-negative breast cancers. Another report 22 showed that miR-206 represses both ERa mRNA and protein expression.
Chemotherapeutic agents, such as paclitaxel, topotecan, 5-fluorouracil, are important in treating breast Abbreviations: ABCG2, ATP-binding cassette, sub-family G(WHITE), member 2; Bcl-2, B-cell CLL/lymphoma 2; Bcl-6, B-cell CLL/lymphoma 6; BIM, Bcl-2 interacting mediator of cell death; BRCA1, breast cancer 1, early onset; CLL, chronic lymphocytic leukemia; C-myc, cellular myelocytomatosis oncogene; CYP1B1, cytochrome P450, family 1, subfamily B, polypeptide 1; ERa, estrogen receptor a; MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia sequence 1; M-CSF, macrophage colony-stimulating factor 1; MDR1, multidrug resistance 1; miRNA, microRNA; NOTCH1, Notch homolog 1, translocation-associated (Drosophila); P-gp, P-glycoprotein 1; PTEN, phosphatase and tensin homolog; SIRT1, Silent mating type information regulation 2 homolog 1; TGF, transforming growth factor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand. miR-145 and miR-155, which were downregulated in MCF-7/AdrVp cells, were shown to be associated with chemosensitivity. The pathway mapping indicated that they were related to axon guidance signaling pathway, insulin signaling pathway and mitogen-activated protein kinase signaling pathways. 28 miR-328 downregulated ABCG2 expression in mitoxantrone-resistant MCF-7/MX100 cells results in increased drug sensitivity. 29 Resistance to chemotherapy distinguishes cancer stem cells (or tumor-initiating cells) from other cancer cells. 30 Expression of let-7 as well as miR-15a, miR-16, miR-21 was reduced in tumor-initiating SK-third cells, compared with their differentiated progeny and the parent line SKBR3. Yu et al. 31 also showed that reduced let-7 is an intrinsic property of BT-IC (and possibly early precursor cells) but not a consequence of exposure to chemotherapy.
Ovarian cancer
Ovarian cancer is the deadliest cancer of the female reproductive system. In advanced ovarian cancer the first line of chemotherapy is the combination of carboplatin/ cisplatin with paclitaxel or other chemotherapy agents. Approximately 20% of the patients do not respond at the first cycle. Up to three-quarters of the drug-sensitive patients relapse after a few years from the first cycle of therapy and tend to respond poorly to the additional chemotherapy agents, such as doxorubicin and vinblastine.
miR-214 is highly expressed in the cisplatin-resistant cell line A2780CP compared with cisplatin-sensitive cell line A2780S. 32 Expression of miR-214 in cisplatinresistant ovarian cancer patients was also examined. Locked nucleic acid in situ hybridization (LNA-ISH) analysis revealed that miR-214 levels were low or undetectable in eight primary tumors but elevated in their recurrent lesions, the remaining three tumors expressed high level of miR-214 in both primary and recurrent tumors. 0 UTR leading to inhibition of PTEN translation and activation of Akt pathway, 32 Akt is a major cell survival pathway and its activation has a key role in multiple drug resistance. These findings indicate that miR-214 has an important role in cisplatin resistance in ovarian cancer by targeting PTEN/Akt pathway.
Let-7i expression was significantly reduced in chemotherapy-resistant ovarian cancer patients and lower let-7i expression is strongly associated with shorter progressionfree survival. In vitro study showed that reduced let-7i expression significantly increased the resistance of ovarian cancer cells to cisplatin. Although the molecular mechanism of let-7i downregulation in patients with chemoresistant ovarian cancer is unclear, Yang et al. 33 have shown that DNA copy number alteration might not affect the expression of let-7i, maybe there are other unknown mechanisms reduce let-7i expression in the chemoresistant patients.
miR-30c, miR-130a and miR-335 were downregulated in paclitaxel-(A2780TAX, A2780TC1/TC3) and cisplatinresistant (A2780CIS) cells of ovarian cancer. Downregulation of miR-130a was linked to the translational activation of macrophage colony-stimulating factor (M-CSF) gene and indicated that M-CSF is a direct target of miR-130a by luciferase targeting assay. 34 M-CSF gene is previously described as a chemoresistant factor, 35 whose upregulation could contribute to the chemoresistant phenotype. Let-7e was upregulated in A2780TAX cells, while it was downregulated in A2780CIS and A2780TC1/TC3 cell lines, in contrast, miR-125b, which was downregulated in A2780TAX cell line, was upregulated in the other cell lines. Previous studies have shown that A2780TAX cell line is P-gp-positive while A2780TC1/TC3 cell line is P-gp-negative. It is suggested that let-7e and miR-125b were diversely regulated in P-gp-positive versus P-gpnegative chemoresistant cells. 34 However, further studies need to be conducted.
Zhu et al. 36 showed the roles of miRNAs in the regulation of drug resistance mediated by MDR1/P-gp. Expressions of miR-27a, miR-451, miR-99a, miR-100 and miR-125b1 were upregulated in human MDR ovarian cancer cell line A2780DX5 and human cervical carcinoma cell line KB-V1, as compared with their parental cell lines A2780 and KB-3-1. Transfection of A2780DX5 cells with the antagomirs of miR-27a or miR-451 resulted in the reductions of both P-gp and MDR1. In contrast, the mimics of miR-27a and miR-451 increased MDR1 expression in the parental A2780 cells. In addition, they showed that treatment with the antagomir of miR-27a or miR-451 increased the sensitivity of A2780DX5 cells to vinblastine and increased the intracellular accumulation of doxorubicin, both drugs are transported by P-gp. In contrast, the sensitivity to hydroxyurea, a non-P-gp substrate chemotherapeutic agent, was not affected by inhibition of miR-27a with its antagomir. Taken together, the sensitivity to and intracellular accumulation of chemotherapeutic agents that are transported by P-gp were enhanced by the treatment with the antagomirs of miR-27a or miR-451. However, transfection of miR-99a, miR-100 and miR-125b1 with antagomirs and mimics did not affected MDR1/P-gp expression. Overexpression of these miRNAs in the MDR ovarian cancer cells suggests a role of these miRNAs in the activation of other genes associated with the development of drug resistance in ovarian cancer.
Lung cancer
Blower et al. 37 found miR-21 had a significant influence on drug potency in human non-small cell lung cancer cell line A549. NSC 621888, NSC 622700 and NSC 670550 showed an increase in potency with decreasing miR-21 levels in A549 cells. This suggests that miR-21 acted as a chemoresistant factor for those compounds. Inhibition of miR-21 resulted in the lower levels of the Bcl-2 protein, which is not a direct target but may be partly responsible for increased apoptosis and drug sensitivity. In contrast, the other two compounds, NSC 63878 (cytarabine, a DNA synthesis inhibitor) and NSC 265450 (nogamycin, a DNA intercalator) showed an increase in sensitivity of A549 cells with increasing miR-21 level. Inhibition of miR-16 decreased the sensitivity of A549 cells to NSC 236613 (plumbagin, an inhibitor of AKT activation) and NSC 670550 while inhibition of let-7i increased the sensitivity to NSC 670550. All the above findings indicate that miRNAs act differently in affecting chemosensitivity in different compounds.
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a relatively new member of the tumor necrosis factor family, which is known to induce apoptosis in a variety of cancers. Treatment with TRAIL induces programmed cell death in a wide range of transformed cells without producing significant effects in normal cells. 38, 39 However, a significant proportion of human cancer cells are resistant to TRAIL-induced apoptosis. To identify novel mechanisms implicated in TRAIL resistance in non-small cell lung cancer, Garofalo et al. 40 performed miRNAs expression profile in TRAILresistant cell line (CALU-1), semi-resistant cell lines (A459 and A549) and TRAIL-sensitive cell line (H460). Microarray analysis indicated that miR-222, miR-100, miR-221, miR-125b and miR-15b were significantly overexpressed in TRAIL-resistant non-small cell lung cancer cells, while downregulation occurred for only two miRNAs, miR-9 and miR-96. They also showed that TRAIL-sensitive H460 cells become resistant to TRAIL when treated with miR-221 and miR-222 pre-miRs. Conversely, transfection with anti-miR-221 and anti-miR-222 rendered TRAIL-resistant CALU-1 cells sensitive to TRAIL. Although the receptor tyrosine kinase Kit and the cyclin-dependent kinase inhibitor p27kip1 are both known as functional targets of miR-221 and miR-222, 15, [41] [42] [43] Garofalo et al. 40 have shown that silencing of p27kip1, but not Kit, increases TRAIL resistance, indicating that the effects of miR-221 and miR-222 on TRAIL resistance are mainly mediated by p27kip1.
Prostate cancer
Prostate cancers are generally androgen-sensitive at the initial diagnosis and as a result, most of the patients are treated with anti-androgen therapy. However, many patients eventually develop androgen-refractory tumors. PC3 and DU145 cell lines are androgen-refractory and resistant to most of anticancer drugs. Expression of miR-34a was markedly decreased in p53-null PC3 and p53-mutated DU145 cells compared with the androgensensitive LNCaP cells expressing wild-type p53 and the normal human prostate epithelial PrEC cells. 44 Another author 45 has recently reported that the SIRT1 (silent mating type information regulation 2 homolog 1) promoter activity as well as its mRNA and protein expression levels were upregulated in PC3 and DU145 cells compared with LNCaP cells. Fujita et al. 44 have shown that both the SIRT1 mRNA and protein levels are downregulated by ectopic miR-34a expression in PC3 cells. It suggested that miR-34a can enhance chemosensitivity through downregulating expression of SIRT1 directly. SIRT1 is an nicotinamide adenine dinucleotide (NAD) -dependent histone/protein deacetylase, which has been shown to be involved in the development of drug resistance in cancer. 46 Fujita et al. 44 reported that SIRT1 is unlikely to be a direct target of miR-34a in spite of the presence of a potential miR-34a-binding site within its 3 0 UTR. They found that SIRT1 inhibition is mediated at the transcriptional level but not at the post-transcriptional level in PC3 cells. Another report 47 has shown that miR34a targets the same potential binding site within the SIRT1 3 0 UTR in HCT116 human colon carcinoma cells, in which miR-34a downregulated SIRT1 protein expression, but did not affect its mRNA level. The above results indicated that binding characteristics of miR-34a to the target and its effects on gene regulation may be different in different cancer cells.
E2F3, one of known direct target of miR-34a, has been shown to regulate E2F1 expression at the transcriptional level. 48 E2F1 can bind to the SIRT1 promoter and positively regulate SIRT1 transcription. 49 Expression levels of proteins involved in cell cycle control and apoptosis such as E2F3, E2F1 and Bcl-2 were decreased in PC3 cells as a result of ectopic expression of miR-34a, suggesting that miR-34a can enhance chemosensitivity through downregulating expression of SIRT1 indirectly. 44 Furthermore, ectopic miR-34a expression can enhance the sensitivity to camptothecin by inducing apoptosis. 44 Tong et al. 50 have recently shown that five miRNAs (miR-23b, miR-100, miR-145, miR-221 and miR-222) were significantly downregulated in malignant tissues from patients with prostate cancer. miR-221 and miR-222 have been shown to have an important role in chemoresistance in estrogen-dependent breast cancer. The prostate cancer is also a hormone-dependent malignancy-like breast cancer. Elucidating the modulation and the molecular targets or the mechanism of miR-221 and miR-222 in the chemoresistance of prostate cancer will be helpful for successful chemotherapy in the future.
Gastric cancer
In many cases therapies fail because of MDR of cancer cells either intrinsic or acquired after an initial round of treatment. 51 Xia et al. 52 analyzed the possible role of miRNAs in the development of MDR in gastric cancer cells. They showed the profile of miRNA expression and revealed downregulation of miR-15b and miR-16 in MDR gastric cancer cell line SGC7901/VCR compared with its parental cell line SGC7901. In vitro drug sensitivity assay showed that overexpression of miR-15b or miR-16 could sensitize SGC7901/VCR cells to vincristine, doxorubicin, etoposide and cisplatin whereas inhibition of the expression would confer SGC7901 cells resistant to the above-mentioned drugs.
The development of drug resistance in various cancer cells has been linked to the reduced susceptibility to druginduced apoptosis, which was shown to be a consequence of overexpression of anti-apoptotic proteins, such as Bcl-2.
53 miR-15b and miR-16 directly inhibit Bcl-2 expression at post-transcriptional level by binding to the 3 0 UTR, 52 suggesting that Bcl-2 is a direct target of miR-15b and miR-16. These data suggest a role for miR-15 and miR-16 in modulating sensitivity to chemotherapeutics in gastric cancer through the regulation of Bcl-2.
It has been shown that Bcl-2 is a direct target of miR-34.
54-57 A recent report stated that miR-34 restoration in gastric cancer Kato III cells (which has mutant p53, low level of miR-34, and high level of Bcl-2.) rendered the cells more sensitive to doxorubicin, cisplatin, gemcitabine and docetaxel, as compared with the cells transfected with the mimic. 57 Restoration of miR-34 in gastric cancer MKN-45 cells, which have a low level of Bcl-2 and a high level of miR-34, showed no chemosensitization. 57 It has suggested that miR-34a can enhance chemosensitivity through downregulation of Bcl-2 directly and possible restoration of p53 function in p53-mutant gastric cancer. In addition, miR-34 may also be involved in the stem cell self-renewal and differentiation by modulation of downstream targets Bcl-2, Notch and HMGA2 in gastric cancers. 57 Further studies are needed to determine the exact role of miRNAs in the chemoresistance of cancer stem cells.
Colon cancer
Kenneth et al. 58 have shown that ABCG2 mRNA adopts a longer 3 0 UTR in the parental S1 colon cancer cell line than its mitoxantrone-resistant counterpart S1MI80. HsamiR-519c decreases ABCG2 mRNA and protein levels by acting through a putative binding site located within the longer 3 0 UTR in parental cells, but the binding site for this miRNA is lost in the shorter 3 0 UTR in the resistant cells, therefore mRNA degradation and/or repression on protein translation is relieved, which contributes to the overexpression of ABCG2. These findings suggest that escaping from miRNA-mediated translational repression and mRNA degradation could lead to overexpression of ABCG2 in drug-resistant colon cancer cells.
Another putative miRNA (hsa-miR-520h) was reported to target ABCG2 in hematopoietic stem cells during their differentiation into progenitor cells. 59 In S1 and S1MI80 cells, hsa-miR-520h binds to both long and short 3 0 UTR of ABCG2. The expression of hsa-miR-520h was less in S1MI80 cells than in S1 cells.
Hsa-let-7g and hsa-miR-181b were also shown to be associated with chemosensitivity to S-1 (a fourthgeneration 5-fluorouracil)-based chemotherapy in colon cancer. 60 The roles of hsa-let-7g and hsa-miR-181b in chemosensitivity are associated with their regulation of several genes such as RAS, cyclin D, C-MYC, E2F and cytochrome C. These genes have been shown to be important for the transduction of cell signals, the control of cell cycles and chemosensitivity. However, the detailed molecular and cellular mechanisms of hsa-let-7g and hsamiR-181b in mediating translational control will require further studies to elucidate the link of these miRNAs in chemosensitivity to fluoropyrimidine-based drugs in colon cancer.
Squamous carcinoma and hepatocellular carcinoma
Apoptotic cell death is one of the factors determining the sensitivity of cancer cells to chemotherapeutic drugs. Caspase-3 leads to programmed cell death. A recent study 61 showed that caspase-3 was the target of let-7a as the ectopic expression of let-7a has decreased the activity of caspase-3 in human squamous carcinoma A431 cells and hepatocellular carcinoma HepG2 cells. Moreover, let-7a was overexpressed while caspase-3 was downregulated in A10A cells (a doxorubicin-resistant A431 subline) compared with the parental A431 cells.
Overexpression of let-7a increased the resistance of A431 cells and HepG2 cells to apoptosis induced by chemotherapeutic agents including interferon-g, doxorubicin and paclitaxel. In contrast, downregulation of let-7a using the anti-let-7a inhibitor increased the doxorubicin-induced apoptosis in A10A cells and HepG2 cells, while the apoptosis was suppressed by caspase-3 inhibitor. However, neither anti-let-7a inhibitor nor caspase-3 inhibitor affect the drug-induced apoptosis in human breast cancer MCF7 cells, which do not express caspase-3. 61 Therefore, through targeting caspase-3, let-7a may have a functional role in modulating drug-induced cell death in human squamous carcinoma and hepatocellular carcinoma.
Cholangiocarcinoma
Cholangiocarcinoma is highly resistant to chemotherapy. Dysregulation of the inflammation-associated cytokine interleukin-6-dependent survival signaling pathways may contribute to the resistance of cholangiocarcinoma to most chemotherapeutic agents. 62, 63 Meng et al. 64 provided evidence that several selective miRNAs including let-7a are upregulated and contribute to the survival effects of enforced interleukin-6 activity, indicating that miRNAs miRNA and drug resistance J Ma et al especially let-7a may be involved in the drug resistance of cholangiocarcinoma. Another report 65 showed that the inhibition of miR-21 and miR-200b increased the sensitivity of cholangiocytes to gemcitabine. Gemcitabine induces upregulation of both miRNAs in vivo. Furthermore, they showed that miR-21 modulates gemcitabineinduced apoptosis by deletion of phosphatase and tensin homolog-dependent activation of PI 3-kinase signaling.
In cholangiocarcinoma, overexpression of Mcl-1 can cause resistance to TRAIL-induced apoptosis while suppression of it sensitizes the cells to apoptosis. 66 Mcl-1, which is a potent multidomain anti-apoptotic protein of the Bcl-2 family, is a potential target of miR-29 as it binds to the 3 0 UTR region of Mcl-1 mRNA and enforced miR-29b expression reduces cellular Mcl-1 protein levels. 67 miR-29b was downregulated in human cholangiocarcinoma cells, so enforced miR-29b expression may reduce the expression of Mcl-1 and sensitize the cholangiocarcinoma cells to TRAIL cytotoxicity. However, much work needs to be carried out to validate the exact mechanisms.
Neuroblastoma
Neuroblastoma is one of the most common extra-cranial solid tumors of early childhood. MYCN amplification occurs in 25% of neuroblastomas, which correlates to an aggressive phenotype and causes resistance to chemotherapy. The miRNA 17-5p-92 cluster, which comprises seven miRNAs, including miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1, are transcribed as a polycistronic unit. 68 Fontana et al.
69
found that MYCN, expressed at elevated level in neuroblastoma, transactivated the miRNA 17-5p-92 cluster by directly binding to its promoter, and knocking down of miR-17-5p was sufficient to promote massive apoptosis of MYCN-amplified cells. The findings indicate that miR-17-5p may be a key factor in inducing protection from MYCN-primed apoptosis in neuroblastoma. In vitro or in vivo treatment with antagomir-17-5p abolishes the growth of MYCN-amplified and chemoresistant neuroblastoma through upregulation of p21 and BIM (Bcl-2 interacting mediator of cell death), leading to the blockade of cell cycling and activation of apoptosis, respectively.

Leukemia
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia in the western world. Loss of 17p (TP53) has been associated with failure to respond to chemotherapy in CLL. 70 However, in chemotherapy-resistant CLL, only 30-40% of cases have a deletion or mutation of TP53, the reason of chemoresistance of the remaining cases is still unknown. Thorsten et al. 71 studied miR-34a and miR-34b/c expression in a large cohort of CLL patients to show their potential role in chemoresistant CLL. They showed that 53% (8 out of 15) of the patients with low miR-34a expression were resistant to fludarabine in the absence of 17p deletion/TP53 mutation, indicating that miR-34a expression is associated with fludarabineresistant in CLL. Further studies are needed to elucidate the mechanisms underlying miR-34a regulation and to overcome its role in chemotherapy resistance.
Recent evidence has shown that two miRNAs, miR-15-a and miR-16-1, are deleted or downregulated in the majority of CLLs. 72, 73 The two miRNAs have already been shown to promote apoptosis by negatively regulating Bcl-2 in CLL cells. 74 Considering the fact that Bcl-2 is expressed in many tumors and involved in drug resistance, miR-15 and miR-16 may be the new therapeutic agents in the future.
Conclusion
In conclusion, the common science discussed in this paper suggests that miRNAs have an important role in the development of chemosensitivity or chemoresistance in different cancers. It is clear that more than one target or mechanism of drug resistance is activated in certain drugs. The targets or mechanisms that can be activated with more than one drug are more attractive for the broad therapeutic potential. miRNAs or antagomiRNAs might be more efficient in avoiding resistance or increasing the effectiveness of malignant tumors to chemotherapy. Furthermore, miRNAs might be used as a biomarker to predict the response to chemotherapy and the survival in patients with malignant tumors. In addition, miRNAs combined with traditional chemotherapy agents might provide a new strategy to treat malignant tumors in the future.
